Education
About Us
Working with TipRanks
Follow Us
Inovio Pharmaceuticals (INO)
NASDAQ:INO
INO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.74 - $14.75
Previous CloseN/A
Volume1.36M
Average Volume (3M)712.00K
Market Cap
$70.40M
Enterprise Value$90.29M
Total Cash (Recent Filing)$14.31M
Total Debt (Recent Filing)$30.21M
Price to Earnings (P/E)―
Beta1.64
Next Earnings
May 13, 2025EPS Estimate
-0.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.98
Shares Outstanding36,667,220
10 Day Avg. Volume742,245
30 Day Avg. Volume712,003
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)323.30
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market Cap1.28
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-33.80
Enterprise Value/Ebitda-0.82
Forecast
1Y Price Target
$6.67Price Target Upside254.79% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessThe company presented full safety and efficacy data for the Phase 1/2 trial of INO-3107 in recurrent respiratory papillomatosis, showing a 72% overall response rate.
Regulatory ProgressINO-3107 has been granted Breakthrough Therapy designation, which could qualify it for priority review.
Bears Say
Financial ConcernsThe company may need to raise additional capital within the next 12 months.
Project DiversificationThe company's operations are solely focused on INO-3107 during 2025, which may limit diversification in their project pipeline.
---
Ownership Overview
0.69% Insiders
6.73% Mutual Funds
16.02% Other Institutional Investors
68.81% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
INO FAQ
What was Inovio Pharmaceuticals’s price range in the past 12 months?
Inovio Pharmaceuticals lowest stock price was $1.74 and its highest was $14.75 in the past 12 months.
What is Inovio Pharmaceuticals’s market cap?
Inovio Pharmaceuticals’s market cap is $70.40M.
When is Inovio Pharmaceuticals’s upcoming earnings report date?
Inovio Pharmaceuticals’s upcoming earnings report date is May 13, 2025 which is in 49 days.
How were Inovio Pharmaceuticals’s earnings last quarter?
Inovio Pharmaceuticals released its earnings results on Mar 18, 2025. The company reported -$0.65 earnings per share for the quarter, beating the consensus estimate of -$0.837 by $0.187.
Is Inovio Pharmaceuticals overvalued?
According to Wall Street analysts Inovio Pharmaceuticals’s price is currently Undervalued.
Does Inovio Pharmaceuticals pay dividends?
Inovio Pharmaceuticals does not currently pay dividends.
What is Inovio Pharmaceuticals’s EPS estimate?
Inovio Pharmaceuticals’s EPS estimate is -0.69.
How many shares outstanding does Inovio Pharmaceuticals have?
Inovio Pharmaceuticals has 36,667,220 shares outstanding.
What happened to Inovio Pharmaceuticals’s price movement after its last earnings report?
Inovio Pharmaceuticals reported an EPS of -$0.65 in its last earnings report, beating expectations of -$0.837. Following the earnings report the stock price went down -6.667%.
Which hedge fund is a major shareholder of Inovio Pharmaceuticals?
Currently, no hedge funds are holding shares in INO
---
Inovio Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.67 (254.79% Upside)
$6.67 (254.79% Upside)
Blogger Sentiment
Bullish
INO Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 286.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 2.3%
Last 30 Days ▲ 2.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-83.82%
12-Months-Change
Fundamentals
Return on Equity
-115.42%
Trailing 12-Months
Asset Growth
-33.56%
Trailing 12-Months
Company Description
Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
---
INO Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements such as resolving key manufacturing issues, demonstrating durable clinical benefits of INO-3107, and advancing the DMAb platform. However, challenges remain with pending FDA submissions and a decline in the cash position.Read More>---
INO Stock 12 Month Forecast
Average Price Target
$6.67
▲(254.79% Upside)
Technical Analysis
Best Analysts Covering INO
1 Year
1 Year Success Rate
0/10 ratings generated profit
1 Year Average Return
-68.19%
reiterated a buy rating 4 months ago
Copying Hartaj Singh's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -68.19% per trade.
---